Results 31 to 40 of about 9,857 (174)

Ceftazidime/Avibactam Resistance in Carbapenemase-Producing Klebsiella pneumoniae

open access: yesEmerging Infectious Diseases, 2023
We identified a novel ceftazidime/avibactam resistance mechanism in sequence type 11 Klebsiella pneumoniae carbapenemase 2–producing K. pneumoniae.
Qiaozhen Cui   +6 more
doaj   +1 more source

Ceftazidime-Avibactam With or Without Aztreonam Versus Other Active Antimicrobials in the Treatment of Bloodstream Infections by Carbapenem-Resistant Klebsiella pneumoniae. [PDF]

open access: yesInfect Dis Ther
Introduction Carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infections (BSIs) are associated with high mortality and limited treatment options.
da Fonseca RC   +13 more
europepmc   +2 more sources

Clinical Efficacy of Ceftazidime-Avibactam in the Treatment of Infections Caused by Carbapenem–Resistant Gram-Negative Bacteria

open access: yesАнтибиотики и Химиотерапия, 2021
The wide spread of carbapenemases among gram-negative bacteria of the Enterobacterales order in hospitals around the world, including Russia, creates great difficulties in the effective use of antibiotics for these infections in the ICU.
S. V. Yakovlev
doaj   +1 more source

Ceftazidime-avibactam

open access: yesRevista Española de Quimioterapia, 2022
The increase in nosocomial infections by beta-lactamase producing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, multidrug-resistant Pseudomonas aeruginosa,
openaire   +2 more sources

Evaluating the efficacy of ceftazidime/avibactam plus amikacin combination therapy as a carbapenem-sparing agent against ceftazidime/avibactam-resistant <i>Escherichia coli</i> using a hollow fiber infection model: a proof-of-concept study. [PDF]

open access: yesAntimicrob Agents Chemother
Carbapenems, often regarded as the last line of defense in treatment of urinary tract infections and urosepsis caused by Escherichia coli, are under pressure from emerging resistance.
Walker MM   +8 more
europepmc   +2 more sources

In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017–2021

open access: yesJournal of Global Antimicrobial Resistance, 2023
: Objectives: To report the in vitro susceptibility of Enterobacterales (n = 3905) and Pseudomonas aeruginosa (n = 1,109) isolates, collected from patients in sub-Saharan Africa (four countries) in 2017–2021, to a panel of 10 antimicrobial agents with a
Mark G. Wise   +12 more
doaj   +1 more source

Analysis of the clinical application of ceftazidime-avibactam in China

open access: yesJournal of Infection and Public Health, 2022
The efficacy and safety of ceftazidime-avibactam were mainly reported in phase II and phase III clinical trials, rarely in the real-world study. The limited real-world study which evaluated the clinical response of this drug shown inconsistent results.
Qing Wang, Ping Xu, Yangang Zhou
openaire   +3 more sources

Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016)

open access: yesAntimicrobial Resistance and Infection Control, 2020
Background This study reports the global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam using data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program between 2012 and 2016.
Hui Zhang   +12 more
doaj   +1 more source

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa

open access: yesAntibiotics, 2021
Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and ...
George L. Daikos   +6 more
doaj   +1 more source

IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND COLISTIN AGAINST CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA CLINICAL ISOLATES

open access: yesİstanbul Tıp Fakültesi Dergisi, 2022
Objective: Infections caused by multi drug-resistant Gram-negative bacilli are increasingly reported worldwide. Ceftazidime-avibactam is a novel antibiotic combination that presents good activity against carbapenem-resistant Enterobacterales members and ...
Tuğrul Hoşbul   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy